Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

被引：0
|
作者：
Touzeau, Cyrille
Moreau, Philippe
Perrot, Aurore
Hulin, Cyrille
Dib, Mamoun
Tiab, Mourad
Caillot, Denis
Facon, Thierry
Leleu, Xavier
van de Donk, Niels W. C. J.
Broijl, Annemiek
Zweegman, Sonja
Levin, Mark-David
Delforge, Michel
Pei, Lixia
Vanquickelberghe, Veronique
De Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Sonneveld, Pieter
机构：
[1] Ctr Hosp Univ, Nantes, France
[2] Univ Hosp Hotel Dieu, Hematol, Nantes, France
[3] Univ Canc Inst IUCT, Hematol Dept, Toulouse, France
[4] Univ Hosp Bordeaux, Dept Hematol, Hop Haut Leveque, Pessac, France
[5] CHRU, Hop Bocage, Angers, France
[6] CHD Vendee, La Roche Sur Yon, France
[7] CHU Dijon, Hop Bocage, Dijon, France
[8] Univ Lille, Serv Malad Sang, CHU Lille, Lille, France
[9] CHU Poitiers, Hop Miletrie, Poitiers, France
[10] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[11] Erasmus MC, Canc Inst, Rotterdam, Netherlands
[12] Albert Schweitzer Hosp, Dordrecht, Netherlands
[13] Univ Ziekenhuizen Leuven, Leuven, Belgium
[14] Janssen Res & Dev LLC, Raritan, NJ USA
[15] Janssen Res & Dev, Beerse, Belgium
[16] Janssen Res & Dev LLC, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8538
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj, Karim
    Karlin, Lionel
    Benboubker, Lotfi
    Levin, Mark-David
    Minnema, Monique C.
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126
  • [2] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj-Merzoug, Karim
    Karlin, Lionel
    Benboubker, Lofti
    Levin, Mark-David
    Minnema, Monique
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3
  • [3] Daratumumab (DARA) plus Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
    Corre, Jill
    Vincent, Laure
    Moreau, Philippe
    Hebraud, Benjamin
    Hulin, Cyrille
    Bene, Marie
    Broijl, Annemiek
    Caillot, Denis
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Perrot, Aurore
    Zweegman, Sonja
    Hua, Winnie
    Krevvata, Maria
    Vanquickelberghe, Veronique
    Tuozzo, Alba
    Rowe, Melissa
    Carson, Robin
    Wuilleme, Soraya
    Avet-Loiseau, Herve
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S29 - S30
  • [4] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Garderet, Laurent
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Sonneveld, Pieter
    Levin, Mark-David
    Klein, Saskia
    Chiu, Christopher
    Pei, Lixia
    De Boer, Carla
    Kampfenkel, Tobias
    Wuilleme, Soraya
    Bene, Marie-Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
    Moreau, Philippe
    Attal, Michel
    Hulin, Cyrille
    Bene, Marie-Christine
    Broijl, Annemiek
    Caillot, Denis
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Perrot, Aurore
    Zweegman, Sonja
    Ahmadi, Tahamtan
    Chiu, Christopher
    Pei, Lixia
    Vermeulen, Jessica
    Avet-Loiseau, Herve
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
    Moreau, Philippe
    Hulin, Cyrille
    Perrot, Aurore
    Arnulf, Bertrand
    Belhadj, Karim
    Benboubker, Lotfi
    Zweegman, Sonja
    Caillon, Helene
    Caillot, Denis
    Avet-Loiseau, Herve
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Sonntag, Cecile
    Fontan, Jean
    Mohty, Mohamad
    Jie, Kon-Siong
    Karlin, Lionel
    Kuhnowski, Frederique
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Orsini-Piocelle, Frederique
    Roussel, Murielle
    de Colella, Jean Marc Schiano
    van de Donk, Niels W. C. J.
    Wuilleme, Soraya
    Broijl, Annemiek
    Touzeau, Cyrille
    Tiab, Mourad
    Marolleau, Jean-Pierre
    Meuleman, Nathalie
    Vekemans, Marie-Christiane
    Westerman, Matthijs
    Klein, Saskia K.
    Levin, Mark-David
    Offner, Fritz
    Escoffre-Barbe, Martine
    Eveillard, Jean-Richard
    Garidi, Reda
    Hua, Winnie
    Wang, Jianping
    Tuozzo, Alba
    de Boer, Carla J.
    Rowe, Melissa
    Vanquickelberghe, Veronique
    Carson, Robin
    Vermeulen, Jessica
    Corre, Jill
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
  • [7] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Caillot, Denis
    Lenain, Pascal
    Benboubker, Lofti
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    Vanquickelberghe, Veronique
    Cote, Sarah
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E200 - E201
  • [8] Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.
    Hulin, Cyrille
    Moreau, Philippe
    Attal, Michel
    Belhadj, Karim
    Benboubker, Lotfi
    Caillot, Denis
    Facon, Thierry
    Garderet, Laurent
    Kuhnowski, Frederique
    Stoppa, Anne-Marie
    Kolb, Brigitte
    Tiab, Mourad
    Sonneveld, Pieter
    Jie, Kon-Siong
    Westerman, Matthijs
    Pei, Lixia
    Kampfenkel, Tobias
    De Boer, Carla
    Vermeulen, Jessica
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching
    Moreau, Philippe
    Hulin, Cyrille
    Zweegman, Sonja
    Hashim, Mahmoud
    Hu, Yannan
    Heeg, Bart
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    He, Jianming
    Lam, Annette
    Cote, Sarah
    Sonneveld, Pieter
    EJHAEM, 2021, 2 (01): : 66 - 80
  • [10] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Sonneveld, Pieter
    Dejoie, Thomas
    Zweegman, Sonja
    Merz, Maximilian
    Weisel, Katja
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    de Boer, Carla
    Cote, Sarah
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E201 - E202
12345